Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
العنوان: | Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal |
---|---|
المؤلفون: | Adil Maarouf, L. Daelman, Ayman Tourbah, A Maitrot, M.-P. Chaunu, Caroline Papeix |
المصدر: | Multiple sclerosis (Houndmills, Basingstoke, England). 18(11) |
سنة النشر: | 2012 |
مصطلحات موضوعية: | Adult, Pediatrics, medicine.medical_specialty, Time Factors, Disease, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Drug Administration Schedule, Natalizumab, Multiple Sclerosis, Relapsing-Remitting, Sphingosine, Brain mri, Medicine, Humans, Immunologic Factors, business.industry, Drug Substitution, Fingolimod Hydrochloride, Multiple sclerosis, medicine.disease, Fingolimod, Magnetic Resonance Imaging, Treatment Outcome, Neurology, Relapsing remitting, Propylene Glycols, Asthenia, Immunology, Disease Progression, Female, Neurology (clinical), Epilepsies, Partial, Epilepsy, Tonic-Clonic, business, medicine.drug |
الوصف: | We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation. FTY was started 3.5 months after a two-year NZB treatment. Fifteen days later, she suffered partial repetitive seizures followed by a tonicoclonic seizure. This was associated with attention difficulties and an increased asthenia. Brain MRI follow-up disclosed large demyelinating active lesions in favour of disease reactivation. This case suggests that FTY introduction may occur less than three months after NZB withdrawal. |
تدمد: | 1477-0970 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b50d8969f5c53e6f3651fd331c17287 https://pubmed.ncbi.nlm.nih.gov/23184503 |
حقوق: | CLOSED |
رقم الأكسشن: | edsair.doi.dedup.....6b50d8969f5c53e6f3651fd331c17287 |
قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!